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Abstract
Human Papillomavirus (HPV) is associated with six cancers and widespread immunization with HPV vaccine could
reduce the number of these cancers. Although HPV vaccination rates are available for the state of Illinois and the city of
Chicago, data are limited for specific areas. We assessed rates of HPV vaccine initiation and completion among adolescents in central Illinois and identified factors associated with initiation and completion. This was a retrospective study of
adolescents (aged 11–17) who receive care at the Southern Illinois University Medicine Department of Pediatrics. The outcome variables were HPV vaccination initiation (receipt of ≥ 1 dose) and completion (receipt of ≥ 2 or 3 doses, depending
on age of initiation). Multivariable logistic regressions were used to identify factors associated with HPV vaccine uptake.
A total of 9,351 adolescents were included in the study. Overall, HPV vaccine initiation was 46.2% and completion was
24.7%. In adjusted analyses, adolescents residing in rural areas were 38% and 24% less likely to initiate (aOR = 0.62;
95 CI: 0.54–0.72) and complete (aOR = 0.76; 95 CI: 0.65–0.88) the HPV vaccine compared with those residing in urban
areas. Similarly, adolescents were less likely to initiate and complete the HPV vaccine if they were not update to date on
the hepatitis A, meningococcal, or Tdap vaccinations. HPV vaccination rates in central Illinois were low, and far below
the national average and the Illinois state average. Future directions should include interventions to increase HPV vaccine
uptake, particularly in rural areas.
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The United States (US) is facing a crisis of human papillomavirus (HPV) infection. Currently, one in four people
in the US – nearly 80 million – are infected with a least
one type of HPV [1]. There are an estimated 14 million
new cases of HPV infection each year in the country, and
it is estimated that 80–90% of sexually active people will
acquire HPV in their lifetime [2]. Oncogenic HPV infections contribute to virtually all cases of cervical, 90% of
anal, 69% of vaginal, 60% of oropharyngeal, 51% of vulvar,
and 40% of penile cancers [3] and second primary cancers
[4, 5]. HPV infection is associated with nearly 39,000 cancer cases diagnosed in the US per year [1]. Between 2008
and 2012, approximately 6,070 cancers (including cervical,
vaginal, vulvar, anal, penile, and oral cancers) were attributable to HPV infection in the state of Illinois [6]. Even
though overall cancer incidence has been decreasing in the
US, HPV-related oropharyngeal and anal cancers are some
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of the few cancers with increasing incidence [7, 8]. With
these figures in mind, the use of routine HPV vaccination as
prevention for adolescents is of vital importance.
The Advisory Committee on Immunization Practices
(ACIP) recommends routine HPV vaccination for adolescents between 11 and 12 years of age [9, 10]. Catch-up vaccination is also recommended for both males and females
aged 13–26 years and shared clinical decision making
through age 45 [9, 10]. Despite the efficacy and safety of the
HPV vaccine, uptake has been low compared to other routine vaccinations in adolescents and current rates fall short
of the Healthy People 2030 goal of 80% completion among
adolescents aged 13–15 years old [11]. The 2020 National
Immunization Survey – Teen reported that 75.1% of adolescents aged 13–17 years had received at least one dose of the
HPV vaccine and 58.6% had completed the series – either 2
or 3 doses based on age of initiation [12]. As of 2020, HPV
vaccination initiation and completion for the state of Illinois
was 75.9% (86.3% in the City of Chicago and 73.7% for the
rest of the state) and 63.1% (72.3% in the City of Chicago
and 61.2% for the rest of the state) [12]. For rural areas,
these rates may even be lower. Prior literature has found that
HPV vaccination rates and the odds of initiation and completion among adolescents in rural communities were lower
than their urban counterparts [13]. Although HPV vaccination rates are available for the state of Illinois and the city of
Chicago [12], data are limited for specific areas of the state.
With no data on HPV vaccination rates about adolescents in
central Illinois, it is crucial to estimate vaccination rates so
interventions may be implemented if necessary. This study
aimed to quantify the rates of HPV vaccine initiation and
completion in an academic medical center located in central
Illinois and identify factors associated with vaccine initiation and completion.

Methods
Data collection
The Southern Illinois University School of Medicine Institutional Review Board approved this study. We performed
a retrospective study of all adolescents (aged 11–17) who
had received at least one dose of childhood recommended
vaccines (hepatitis A, hepatitis B, measles, mumps, rubella
[MMR], meningococcal, and tetanus, diphtheria, and pertussis [Tdap]) from January 1, 2015, to December 31, 2020,
at the Southern Illinois University (SIU) Medicine, Department of Pediatrics, division of Pediatric Primary Care,
located in Springfield, IL. The medical center is located in
a small urban area and provides access to care for patients
from surrounding rural counties. The medical center is also

13

a Vaccines for Children (VFC) provider. Electronic medical records were reviewed, and the necessary data were
extracted.

Measures
The outcome variables were HPV vaccine initiation and
completion. Adolescents who had received at least one
dose of the vaccine were deemed to have initiated the vaccination. In Fall of 2016, the ACIP stated that adolescents
who initiated the vaccine at 9–14 years of age need only
two doses received 6 months apart [14]. However, those
who initiated the vaccine at the age of 15 years or older
still need three doses [14]. Based on this recommendation,
adolescents who initiated the vaccine before age 15 years
and received at least two doses or initiated after age 15 years
and received at least three doses were deemed to have completed the series. Independent variables were adolescent age
in years, sex (male, female), race (White, Black/African
American, other), insurance type (private, Medicaid), rural
vs. urban status based on Rural-Urban Continuum codes
(RUCCs; rural: RUCC = 4–7, urban: RUCC = 1–3) and a
yes/no response to hepatitis A vaccine initiation and completion, hepatitis B vaccine initiation and completion, MMR
vaccine initiation and completion, meningococcal vaccination, and Tdap vaccination.

Statistical Analysis
Descriptive characteristics were used to summarize the
study sample, overall and stratified by HPV vaccine initiation and completion. Multivariable binary logistic regression models were used to examine the association between
independent variables (age, sex, race, insurance type, rural/
urban status, hepatitis A vaccine completion, hepatitis B
vaccine completion, MMR vaccine completion, meningococcal vaccination, and Tdap vaccination) and HPV vaccine
initiation and completion. Odds ratios and their associated
95% confidence intervals were reported for all variables.
Statistical tests were two-tailed, and the significance level
was set at P < 0.05. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC).

Results
A total of 9,351 adolescents were included in the study.
There was an equal distribution of age, among females
and males, 75.7% were of White race, 56.8% had private
insurance and 71.9% resided in urban areas (Table 1). Most
adolescents had initiated and completed the hepatitis A and
hepatitis B vaccines. Similarly, the majority had initiated the
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Table 1 Characteristics of adolescents included in the study (n = 9,351)
Frequency (%)
Overall
HPV vaccine initiation
Yes
HPV vaccine initiation
Yes
No
HPV vaccine completion
Yes
No
Age (categorized)
11–12
13–14
≥ 15
Sex
Female
Male
Race
White
Black/African American
Other
Insurance
Private
Medicaid
Rural-Urban status
Urban
Rural
Hepatitis A vaccine initiation
Yes
No
Hepatitis A vaccine completion
Yes
No
Hepatitis B vaccine initiation
Yes
No
Hepatitis B vaccine completion
Yes
No
Meningococcal vaccine initiation
Yes
No
Meningococcal vaccine completion
Yes
No
Measles, mumps, rubella (MMR) vaccine initiation
Yes
No
Measles, mumps, rubella (MMR) vaccine completion
Yes
No
Tetanus, diphtheria, and pertussis (Tdap) vaccination
Yes
No

No

P-value

HPV vaccine
completion
Yes
No

P-value

4317 (46.2)
5034 (53.8)
2313 (24.7)
7038 (75.3)
2482 (26.5) 818 (33.0) 1664 (67.0) < 0.0001 282 (11.4) 2200 (88.6) < 0.0001
2712 (29.0) 1296 (47.8) 1416 (52.2)
877 (32.3) 1835 (67.7)
4157 (44.5) 2203 (51.0) 1954 (47.0)
1154 (27.8) 3003 (72.2)
4649 (49.7) 2241 (48.2) 2408 (51.8) < 0.0001 1213 (26.1) 3436 (73.9) 0.0025
4702 (50.3) 2076 (44.1) 2626 (55.9)
1100 (23.4) 3602 (76.6)
7077 (75.7) 3238 (45.8) 3839 (54.2) < 0.0001 1827 (25.8) 5250 (74.2) < 0.0001
1302 (13.9) 738 (56.7) 564 (43.3)
328 (25.2) 974 (74.8)
972 (10.4) 341 (35.1) 631 (64.9)
158 (16.3) 814 (83.7)
5311 (56.8) 2727 (51.3) 2584 (48.7) < 0.0001 1631 (30.7) 3680 (69.3) < 0.0001
4040 (43.2) 1590 (39.4) 2450 (60.6)
682 (16.9) 3358 (83.1)
6724 (71.9) 3631 (54.0) 3093 (46.0) < 0.0001 1962 (29.2) 4762 (70.8) < 0.0001
2627 (28.1) 686 (26.1) 1941 (73.9)
351 (13.4) 2515 (86.6)
5542 (59.3) 3736 (67.4) 1806 (32.6) < 0.0001 2078 (37.5) 3464 (62.5) < 0.0001
3809 (40.7) 581 (15.3) 3228 (84.7)
235 (6.2)
3574 (93.8)
5077 (54.3) 3471 (68.4) 1606 (31.6) < 0.0001 1984 (39.1) 3093 (60.9) < 0.0001
4274 (45.7) 846 (19.8) 3428 (80.2)
329 (7.7)
3945 (92.3
6822 (72.9) 4212 (61.7) 2610 (38.3) < 0.0001 2291 (33.6) 4531 (66.4) < 0.0001
2529 (27.1) 105 (4.2)
2424 (95.8)
22 (0.9)
2507 (99.1)
6689 (71.5) 4171 (62.4) 2518 (37.6) < 0.0001 2275 (34.0) 4414 (66.0) < 0.0001
2662 (28.5) 146 (5.5)
2516 (94.5)
38 (1.4)
2624 (98.6)
5612 (60.0) 4201 (74.9) 1411 (25.1) < 0.0001 2295 (40.9) 3317 (59.1) < 0.0001
3739 (40.0) 116 (3.1)
3623 (96.9)
18 (0.5)
3721 (99.5)
851 (9.1)
714 (83.9) 137 (16.1) < 0.0001 330 (38.8) 521 (61.2) < 0.0001
8500 (90.9) 3603 (42.4) 4897 (57.6)
1983 (23.3) 6517 (76.7)
6780 (72.5) 4209 (62.1) 2571 (37.9) < 0.0001 2292 (33.8) 4488 (66.2) < 0.0001
2571 (27.5) 108 (4.2)
2463 (95.8)
21 (0.8)
2550 (99.2)
6390 (68.3) 4084 (63.9) 2306 (36.1) < 0.0001 2227 (34.9) 4163 (65.1) < 0.0001
2961 (31.7) 233 (7.9)
2728 (92.1)
86 (2.9)
2875 (97.1)
5660 (60.5) 4219 (74.5) 1441 (25.5) < 0.0001 2292 (40.5) 3368 (59.5) < 0.0001
3691 (39.5) 98 (2.7)
3593 (97.3)
21 (0.6)
3670 (99.4)

meningococcal (60.0%), MMR (72.5%) and Tdap (60.5%)
vaccines. Overall, vaccine initiation for HPV was 46.2%
and completion was 24.7%. In the unadjusted analyses,
there were significant differences between adolescents who

had initiated and completed the HPV vaccine, and all independent variables (Table 1).
In the adjusted analyses (Table 2), older age was associated with increase odds of initiating (aOR = 1.19; 95 CI:
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Table 2 Logistic regression models estimating HPV vaccination
initiation and completion among
adolescents (n = 9,351)

Age (continuous)
Sex
Female
Male
Race
White
Black
Other
Insurance
Private
Medicaid
Rural-Urban status
Urban
Rural
Hepatitis A completion
Yes
No
Hepatitis B completion
Yes
No
Measles, mumps, rubella (MMR) completion
Yes
No
Meningococcal initiation
Yes
No
Tetanus, diphtheria, and pertussis (Tdap)
Yes
No

1.15–1.23) and completing (aOR = 1.10; 95 CI: 1.06–1.13)
the HPV vaccination. However, males were less likely
to initiate (aOR = 0.75; 95 CI: 0.66–0.85) and complete
(aOR = 0.83; 95 CI: 0.75–0.93) the HPV vaccine series
compared with females. Adolescents residing in rural areas
were 38% and 24% less likely to initiate (aOR = 0.62; 95
CI: 0.54–0.72) and complete (aOR = 0.76; 95 CI: 0.65–0.88)
the HPV vaccine respectively compared with those residing
in urban areas. Adolescents were less likely to initiate the
HPV vaccine if they were not up to date on the hepatitis A
(aOR = 0.29; 95 CI: 0.25–0.34), meningococcal (aOR = 0.15;
95 CI: 0.10–0.21) and Tdap (aOR = 0.09; 95 CI: 0.06–0.13)
vaccines. Similarly, adolescents were less likely to complete the HPV vaccine if they were not up to date on the
hepatitis A (aOR = 0.33; 95 CI: 0.28–0.38), meningococcal
(aOR = 0.06; 95 CI: 0.03–0.12) and Tdap (aOR = 0.24; 95
CI: 0.12–0.46) vaccines.

Discussion
The increase in life expectancy in the 20th century is largely
due to improvement in child health care especially curing
or preventing infections [15]. Currently in United States,
the recommendations focus on 17 vaccine-preventable
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Adjusted OR (95% CI)
HPV vaccine initiation
1.19 (1.15, 1.23)
Reference
0.75 (0.66, 0.85)

HPV vaccine completion
1.10 (1.06, 1.13)
Reference
0.83 (0.75, 0.93)

Reference
1.75 (1.43, 2.15)
0.92 (0.74, 1.14)

Reference
0.94 (0.80, 1.11)
0.71 (0.58, 0.88)

Reference
1.10 (0.96, 1.26)

Reference
0.64 (0.56, 0.72)

Reference
0.62 (0.54, 0.72)

Reference
0.76 (0.65, 0.88)

Reference
0.29 (0.25, 0.34)

Reference
0.33 (0.28, 0.38)

Reference
0.99 (0.70, 1.39)

Reference
0.65 (0.43, 0.99)

Reference
1.15 (0.85, 1.55)

Reference
1.01 (0.74, 1.37)

Reference
0.15 (0.10, 0.21)

Reference
0.06 (0.03, 0.12)

Reference
0.09 (0.06, 0.13)

Reference
0.24 (0.12, 0.46)

diseases. This study assessed HPV vaccination rates of
adolescents in a central Illinois urban county and surrounding rural areas. We found that adolescents in our study had
substantially lower HPV vaccination rates than the national
average (initiation: 46.2% vs. 75.1%%) and (completion:
24.7% vs. 58.6%) [12]. The vaccination rates in our study
were also lower than the average for the state of Illinois
[12]. Additionally, adolescents who resided in rural areas
and/or had not completed other adolescent immunizations
had lower HPV vaccination rates than their urban counterparts and those who had completed their childhood vaccinations, respectively. Findings suggest the continued need for
HPV vaccination interventions, particularly in clinics serving patients residing in rural areas.
We found that compared to adolescents residing in urban
counties, those residing in rural counties were less likely to
initiate and complete the HPV vaccine series. This finding
was consistent with other studies that have reported similar
findings [13]. There are many theories on the reasons for differences in vaccination rates between rural and urban areas,
however, it is likely due to multiple factors including cost,
access to health care, transportation barriers, and parental
concerns about vaccines for preventing sexually transmitted
illnesses [16–18]. The reduction in number of doses require
to complete the vaccination might help increase completion
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rates as it will reduce some of the barriers like transportation
issues and access to care.
Moreover, adolescents who had not completed hepatitis A, meningococcal, or Tdap vaccines were less likely
to initiate and complete the HPV vaccination compared to
those that were up to date on those vaccinations. This means
adolescents are not receiving all the necessary vaccinations
that are recommended, including those required for school
(meningococcal and Tdap). It should be noted that HPV and
hepatitis A are not required for school. This could be due
to lack of parental acceptance of vaccines in general and/
or provider recommendation of vaccines including the HPV
vaccine. Healthcare providers should take every visit as an
opportunity to recommend all the childhood vaccinations
for patients who are not up to date.
This study has some limitations. First, this study analyzed
data from one academic medical center and therefore may
not be representative of other areas in the state and nationally. Second, as with many observational studies, there are
other variables we could not adjust for such as provider recommendation that could have affected our findings. Third,
no causal inference could be made about the findings since
this was a cross-sectional study.

Conclusion
We found that HPV vaccination rates among adolescents in
central Illinois were very low, and far below the national
average as well as the state of Illinois average. In addition,
we found that adolescents residing in rural counties were
less likely to initiate and complete the HPV vaccine series
compared to their urban counterparts. Similarly, adolescents who had not completed other childhood vaccinations
(Hep A, Tdap) were less likely to initiate and complete the
HPV vaccination compared to those who had completed the
series.
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